Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma

Abstract

We aimed to determine prognostic factors of early stage (I/II) epithelial ovarian carcinoma (EOC) including clinicopathologic and chemotherapeutic regimens. Four hundred and thirty-seven women who underwent primary staging surgery with adjuvant chemotherapy between January 1, 2000 and December 31, 2010 were retrospectively reviewed and analyzed from two medical centers. The prognostic factors were determined from multivariate survival analyses using Cox regression models. The majority of women were diagnosed with stage Ic (244/437, 55.8%). The histopathologic types were clear cell (37.5%), endometrioid (27.2%), serous (14.0%), and mucinous (13.3%). Fifty-seven percent (249/437) of the women received taxane-based (platinum plus paclitaxel) regimens and 43.0% received non-taxane (platinum plus cyclophosphamide) regimens as frontline adjuvant chemotherapy. Clear cell tumors (adjusted Hazard ratio (aHR) 0.37, 95% confidence interval (CI) 0.21–0.73, p = 0.001) showed better 5-year disease-free survival (DFS) than serous tumors. Women diagnosed at FIGO (International Federation of Gynecology and Obstetrics) stage II (aHR 5.97, 95% CI = 2.47–14.39, p < 0.001), grade 3 tumor without clear cell (aHR 2.28, 95% CI = 1.02–5.07, p = 0.004) and who received 3–5 cycles of non-taxane regimens (aHR 3.29, 95% CI = 1.47–7.34, p = 0.004) had worse 5-year overall survival (OS). Clear cell histology treated with taxane-based regimens showed significantly higher 5-year DFS (91.2% vs. 82.0%, aHR = 0.45, 95% CI = 0.21–0.93, p = 0.043) and 5-year OS (93.5% vs. 79.0%, aHR = 0.30, 95% CI = 0.13–0.70, p = 0.005) than those treated with non-taxane-based regimens. We conclude that stage, tumor grade, and chemotherapeutic regimens/cycles are independent prognostic factors for early stage ovarian cancer.

<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

“…17,20 The difference between the findings of this study and those of other studies could be justified by the fact that antineoplastic drug regimens affect the outcomes of different histologic types especially those of clear cell histology. 12 In contrast to previous studies, in this study, a few numbers of patients with clear cell carcinoma were included and were considered as having other types of tumors. This may be the reason for the difference between the results obtained in the present study and those of the other studies.…”

“…Moreover, no significant differences were found between histologic types and the 5-year OS. 12 To the best of our knowledge, no prior studies have assessed the OS among Iranian women patients with EOC. Therefore, the objective of this study was to evaluate the relationship between OS, stage, and clinicopathologic characteristics of patients with EOC in terms of demographics, survival outcomes, and prognostic factors including histological types.…”

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

“…However, the prognosis of patients with ETOC and PPSC is still disappointing, because of vague or free symptoms of patients, often misdiagnosed as less deadly gastro-enteral tract problems, and the absence of effective screening programs, and, in addition, its heterogeneous nature and different clinical development, accounting for late diagnosis in its advanced stages [52][53][54][55]. All result in a therapeutic challenge, contributing to low cure rate and high mortality rate, [1][2][3][4][5][19][20][21][22][23][24][25].…”

Characterization of Mutational Status, Spheroid Formation, and Drug Response of a New Genomically-Stable Human Ovarian Clear Cell Carcinoma Cell Line, 105C

“…OCCC patients make up to 26% stage I/II ovarian cancer patients and show a good outcome [2,[7][8][9]. However, when OCCC patients present with late stage disease, the outcome is poor because the disease is resistant to conventional epithelial ovarian cancer chemotherapeutics or quickly becomes refractory [10][11][12].…”